• MAPK10–KRT16 Axis Restrains NSCLC Metastasis

  2026-09-20

  The reference study identifies a phosphorylation-dependent MAPK10–KRT16–RNF213 pathway that limits non-small cell lung cancer metastasis by directing KRT16 toward ubiquitination and proteasomal degradation. Its combination of cellular, animal, and clinical evidence positions KRT16 protein turnover, rather than transcription alone, as a useful mechanistic and prognostic framework.

• LY2603618 Chk1 Inhibitor Workflow Guide

  2026-09-18

  LY2603618 provides a focused way to connect Chk1 inhibition with G2/M disruption, DNA damage, and chemotherapy response. This workflow guide shows how to prepare, dose, validate, and troubleshoot the compound while using PARP1-trapping research to sharpen assay design without overstating the evidence.

• Structure-Based Screening of SARS-CoV-2 NSP15 Inhibitors

  2026-09-18

  The reference study used structure-based virtual screening and molecular dynamics simulations to prioritize natural products that may inhibit the SARS-CoV-2 NSP15 endoribonuclease. Thymopentin and oleuropein produced the strongest computational profiles, but biochemical, cellular, and clinical validation remains necessary before their antiviral relevance can be established.

• Benzyl-activated Streptavidin Magnetic Beads Guide

  2026-09-17

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) provide magnetically recoverable capture of biotinylated proteins, peptides, antibodies, oligonucleotides, and nucleic acids from complex samples. They are appropriate for capture, purification, pull-down, screening, and immunoprecipitation workflows, but require compatibility testing for non-biotinylated targets, live-cell exposure, sensitive enzymes, and applications requiring a defined elution method.

• Paroxetine Mesylate: From SSRI to Translational Probe

  2026-09-17

  Paroxetine Mesylate is more than a serotonergic agent: its SERT activity, CYP2D6 interaction, GRK2 inhibition, and MET–ERBB3-linked preclinical oncology findings create a useful but complex translational research probe. This article outlines how to convert that mechanistic breadth into disciplined experimental and strategic decisions.

• STT3A–FCN3 Glycosylation in HCC Progression

  2026-09-16

  A 2026 Cellular Oncology study identifies an STT3A–FCN3–Wnt/β-catenin axis that links protein N-glycosylation to regulatory T-cell activation and hepatocellular carcinoma progression. The work combines clinical association, genetic perturbation, glycosylation-site analysis, cell assays, and xenograft validation, while also clarifying why broad pathway inhibitors require careful interpretation.

• Thioredoxin Control of CHK1 Inhibitor Sensitivity

  2026-09-16

  This Nature Communications study identifies thioredoxin 1 as a determinant of CHK1 inhibitor sensitivity in non-small cell lung cancer and links that effect to redox control of ribonucleotide reductase and deoxynucleotide availability. The findings provide a mechanistic basis for combining CHK1 inhibition with thioredoxin reductase disruption, while also highlighting the need for biomarker-guided validation beyond single-model experiments.

• Sodium Orthovanadate in Cell Signaling Assays

  2026-09-15

  Learn how Sodium Orthovanadate (SKU A8524) can improve phosphorylation-state preservation when viability, proliferation, and cytotoxicity assays are paired with mechanistic signaling analysis. This scenario-based guide covers compatibility, preparation, interpretation, and practical vendor-selection criteria for Na3VO4 workflows.

• Octyl-α-ketoglutarate for HIF-1α Assays

  2026-09-15

  A scenario-based guide to using Octyl-α-ketoglutarate, SKU C4321, to separate metabolic effects from oxygen-dependent HIF-1α regulation in viability, proliferation, and cytotoxicity workflows. It covers experimental controls, handling, interpretation, and practical vendor-selection criteria.

• Azilsartan in Astrocyte–Microglia Research

  2026-09-14

  Azilsartan (TAK-536) extends selective AT1 receptor interrogation beyond blood-pressure models into mechanistic studies of microglia-conditioned astrocyte reactivity. This workflow translates a 2024 study into practical stock-preparation, treatment-design, readout, and troubleshooting decisions for neuroinflammation research.

• Angiotensin (1-7): Mechanism to Translation

  2026-09-14

  Angiotensin (1-7) is more than a counter-regulatory renin–angiotensin system peptide: it is a mechanistic probe for Mas receptor biology, fibrosis, inflammation, metabolism, neuroprotection, and emerging host–pathogen questions. This article connects pathway insight with practical experimental design and translational decision-making.

• 3-Methyladenine Workflows for Autophagy Research

  2026-09-13

  Use 3-Methyladenine to interrogate class III PI3K-dependent autophagy, nutrient-stress responses, and migration phenotypes with time-aware controls. This guide connects practical 3-MA workflows to emerging cuproptosis research while highlighting interpretation limits and troubleshooting strategies.

• Antibiotic Use and Resistance in Psychiatric Hospitals

  2026-09-12

  This retrospective study links antibacterial-drug utilization with bacterial resistance patterns in a psychiatric hospital during the 2022 epidemic. Its main contribution is the integration of hospital prescribing metrics, microbiological submission data, and susceptibility results to inform stewardship in a high-contact psychiatric-care setting.

• Magneto-Piezoelectric Scaffolds Target JAK2-STAT3

  2026-09-11

  This ACS Nano study develops a dual-responsive scaffold that combines magnetic biofilm disruption with ultrasound-triggered metabolic reprogramming of Icam1+ macrophages. Its central contribution is linking JAK2-STAT3 activation and MAPK-JNK suppression to oxidative phosphorylation, pro-reparative immune activity, and improved regeneration of infectious bone defects.

• Z-VDVAD-FMK: Apoptosis Pathway Mapping

  2026-09-11

  Z-VDVAD-FMK helps researchers distinguish caspase-2-linked mitochondrial apoptosis from downstream caspase-3/7 activity and caspase-independent death. This workflow also shows how to use it as a mechanistic control when studying HOXC8-associated pyroptosis in lung cancer models.

8101 records 1/541 page Next 12345 下5页 Last page